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1ABSTRACT
Clinical implication of aminoacyl-tRNA synthetase interacting multi-
functional protein 2–exon 2 deletion variant in lung cancer
Ji Ye Jung
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Joon Chang)
Backgrounds: Aminoacyl-tRNA synthetase interacting multi-functional protein 2 
(AIMP2) promotes cell death through activation of p53 and TNF-α signaling. Its
alternatively spliced form lacking exon 2 (AIMP2-DX2) competes with AIMP2 for 
binding to target proteins, compromising the tumor suppressive activity of 
AIMP2. In this study, the clinical implication and mechanism of AIMP2-DX2
overexpression was investigated in lung cancer. 
Methods: AIMP2-DX2 expression was evaluated by immunohistochemistry (IHC)
and immunoblotting in lung tissues from lung cancer mouse models and surgical 
specimens from lung cancer patients. Autoantibodies against AIMP2-DX2 and 
AIMP2 were measured in the blood from lung cancer patients and controls by 
enzyme-linked immunosorbent assay. 
2Results: AIMP2-DX2 was overexpressed in lung cancer tissues more often than in 
non-neoplastic lung tissues from mice and humans. AIMP2-DX2 overexpression in 
lung cancer tissues was not related with mTORC1 activity. Among various types of 
aminoacyl-tRNA synthetases and anti-apoptotic molecules, AIMP2-DX2 was 
positively correlated with Bcl-xL expression. Transfecting A549 and H460 cells 
with a dominant-negative mutant of signal transducer and activator of transcription 
3 (STAT3) decreased the expression of serine/arginine-rich splicing factor 1 
(SRSF1), AIMP2-DX2, and Bcl-xL. Autoantibodies against AIMP2-DX2 and 
AIMP2 were detectable in the serum of lung cancer patients and controls. A high 
AIMP2-DX2/AIMP2 autoantibody ratio was an independent significant prognostic 
factor for poor clinical outcome in lung cancer patients (hazard ratio = 1.83, 95% 
confidence intervals 1.11 - 3.01).
Conclusions: These findings suggest that AIMP2-DX2 is a useful biomarker for 
lung cancer diagnosis and prediction of prognosis. AIMP2-DX2 warrants further 
study for development as a target molecule in lung cancer.
-----------------------------------------------------------------------------------------------------
Key words: aminoacyl-tRNA synthetase, aminoacyl-tRNA synthetase interacting 
multi-functional protein 2, aminoacyl-tRNA synthetase interacting multi-functional 
protein 2-exon 2 deletion, lung cancer
3Clinical implication of aminoacyl-tRNA synthetase interacting multi-
functional protein 2–exon 2 deletion variant in lung cancer
Ji Ye Jung
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Joon Chang)
I. INTRODUCTION
Lung cancer is the second most common malignancy, with approximately 242,550 
new cases diagnosed in the US in 2014.1 Moreover, lung cancer accounts for more 
than one quarter of all cancer deaths, making it the most common cause of cancer-
related death.1 In Korea, lung cancer was the fourth most common cancer overall 
with 22,118 new cases in 2011, and was most common cancer in male aged 65 years 
or older.2 Lung cancer also showed the highest mortality rate in Korea among all 
cancers.2
Despite efforts toward targeted drug development and biomarker discovery, lung 
cancer has poor prognosis. Understanding the biology and developing new 
4therapeutic strategies based on specific subtypes of lung cancer is needed to 
improve clinical outcomes.
Aminoacyl-tRNA synthetase interacting multi-functional proteins (AIMPs) are 
scaffolding proteins for the assembly of the macromolecular tRNA synthetase 
complex. Among the 3 types of AIMPs, AIMP2 (also known as p38 and JTV1) 
possesses anti-proliferative and cell death-promoting activity through multiple 
pathways such as tumor-derived growth factor (TGF)-β, p53, tumor necrosis 
factor (TNF)-α, and Wnt signaling.3-9 Mice lacking AIMP2 die neonatally 
due to respiratory failure resulting from uncontrolled proliferation of lung 
epithelial cells. AIMP2 heterozygous mouse (with reduced expression of AIMP2)
show a higher susceptibility to tumorigenesis.6 These findings indicate that AIMP2 
is a haploinsufficient tumor suppressor with a unique working mechanism.3
A variant of AIMP2 in which exon 2 is deleted by alternative splicing, AIMP2-DX2, 
has been detected in cancer cell lines and tissues.10 AIMP2-DX2 competes with 
AIMP2 for binding to the target proteins (namely far upstream element binding 
protein [FBP], TNF receptor-associated factor 2 [TRAF2], and p53), 
consequently inhibiting the tumor suppressive activity of AIMP2. Increased ratio of 
AIMP2-DX2 versus AIMP2 showed positive correlation to poor clinical outcome of
lung cancer, as well as chemoresistance of ovarian cancer.3,10 The synthetic 
compound, BC-DXI01 suppressed the AIMP2-DX2 mRNA transcript, leading to the 
inhibition of the AIMP2-DX2 activity and tumor suppression.11 Taken together, 
these data suggest that AIMP2-DX2 is an attractive candidate for cancer diagnosis
5and therapy.11
In this study, AIMP2-DX2 expression was examined in lung cancer using K-ras and 
K-ras:p53fl/fl mouse lung cancer models and human lung cancer tissues to evaluate 
its clinical implications. To explore signaling pathways and mechanisms related to 
AIMP2-DX2 expression, we evaluated the relationship between AIMP2-DX2 
expression and components of mTOR pathway and Bcl-xL, which play a critical 
role in cancer growth and proliferation. Moreover, the presence of autoantibodies 
against AIMP2-DX2 and AIMP2 in the blood was investigated by enzyme-linked 
immunosorbent assay (ELISA). We sought to find the diagnostic and prognostic 
usefulness of these autoantibodies in lung cancer patients.
6II. MATERIALS AND METHODS
1. Tissue samples
Mouse tissues were obtained from wild type C57BL/6, LSL K-ras G12D, and LSL
K-ras G12D:p53fl/fl mice. For mouse lung cancer tissues, LSL K-ras G12D and LSL
K-ras G12D:p53fl/fl mice inhaled 5 ´ 107 PFU AdCre particles at 8 weeks of age and 
were sacrificed 8 and 24 weeks after inhalation, respectively 
(http://mouse.ncifcrf.gov/). This animal study was approved by our Institutional 
Animal Care and Use Committee (2014-0229-1), following the guidelines of the 
American Association for the Assessment and Accreditation of Laboratory Animal 
Care. A total 275 human lung cancer tissues (formalin fixation and paraffin 
embedding (FFPE)), and 12 pairs of lung cancer tissue and adjacent normal lung 
tissue lysates were obtained from tissue archives of affiliated hospitals of Yonsei 
University College of Medicine. The use of clinical samples was approved by the 
Institutional Review Boards of Severance Hospital (#4-2013-0556) and Gangnam 
Severance Hospital (#3-2014-0838).
2. Serum samples
The serum samples from lung cancer patients and control subjects were obtained 
from those who had presented to Severance Hospital and Gangnam Severance 
Hospital between September 2011 and January 2015. Lung cancer cases were 
confirmed pathologically and did not present with any other types of cancer. Control 
cases were 1:1 age-, gender- and smoking status-matched and did not present with 
7any other types of cancer. To exploit their clinical implication, a total 165 samples 
from lung cancer patients were recruited. Informed consent was obtained from all 
study subjects, and all protocols were approved by the above-mentioned review 
boards. The study was carried out in accordance with the Declaration of Helsinki 
and Korean GCP guidelines.
3. Cell lines, chemicals, and antibodies
A549 and H1703 cells were purchased from the ATCC (Manassas, VA, USA). 
H460, H358, H596, H1299, H1650, H2009, and HCC2279 cells were obtained from 
the Korean Cell Line Bank (Seoul, Korea). Anti-AIMP2-DX2, anti-methionyl-
tRNA synthetase (MRS), and anti-leucyl-tRNA synthetase (LRS) antibodies were 
purchased from Neomix Inc (Suwon, Gyeonggi-do, Korea) and other antibodies 
were obtained from Cell Signaling Technology (Danvers, MA, USA).
4. Immunohistochemistry (IHC)
Expression of AIMP2-DX2 in mouse lung tissues and human lung cancer tissues
was analyzed by IHC using the LABS®2 System (Dako, Carpinteria, CA, USA) 
according to the manufacturer's protocol. Briefly, sections were deparaffinized, 
rehydrated, immersed in H2O2 methanol solution, and then incubated overnight with 
primary antibodies against AIMP2-DX2 obtained by rabbit immunization 
(Neomix Inc, Korea) at a 1:2,000 dilution. Sections were incubated for 10 min with 
biotinylated linker and processed using avidin/biotin IHC techniques. 3,3′-
diaminobenzidine (DAB) was used as a chromogen in conjunction with the Liquid 
8DAB Substrate kit (Novocastra, UK). Expression of AIMP2-DX2 was evaluated 
using a scoring system that takes into account the product of staining intensity and 
percentage of positive cells. Staining intensity was classified as 0, 1, 2, or 3 and 
frequency was classified as 0 (<10%), 1 (10-50%), 2 (51-80%), or 3 (>80%). The 
cases were classified into 2 groups according to the AIMP2-DX2 expression in the 
cytoplasm and nucleus. Cases with cytoplasmic AIMP2-DX2 expression equal to or 
greater than 4 were defined as having high expression; those with 3 or less were 
defined as having low expression. Cases with nuclear AIMP2-DX2 expression equal 
to or greater than 1 were defined as having high expression; those with 0 were 
defined as having low expression.
5. Immunoblotting
Tissues were harvested using 2´LSB lysis buffer containing protease and 
phosphatase inhibitors (GenDepot, Korea) on ice. After homogenization and 
sonication, 30-50 mg of lysates was separated by gel electrophoresis on 7.5–12% 
polyacrylamide gels and transferred onto nitrocellulose membranes (Bio-Rad 
Laboratories, Inc., Richmond, CA, USA). The expression level of each protein was 
measured using Image J (http://rsbweb.nih.gov/ij/) and quantified relative to that of 
β-actin.
6. Measurement of serum autoantibodies against AIMP2 and AIMP2-DX2
The 96-well plates were coated with either His-tagged AIMP2-DX2 or His-tagged 
9AIMP2 protein (Neomix Inc, Korea) overnight at 4°C, and then were blocked with 
1% bovine serum albumin for 1 hour at room temperature. After adding 1:500
diluted serum, 1:10,000 diluted anti-human immunoglobulin G was added and 
incubated for another 1 hour at room temperature. The enzyme activity was 
visualized by adding 3,3¢,5,5¢-tetramethylbenzidine substrate (TMB; Thermo Fisher 
Scientific) for 10 minutes and the reaction was stopped by 2N H2SO4. The 
absorbance was measured at 450 nm. The intra-assay variation of AIMP2-DX2 and 
AIMP2 were 8.7 % (6.8-11.5 %) and 6.3 % (1.6-10.4 %), respectively. The inter-
assay (plate-to-plate) variation was 15.9% (13.7%-17.9%) and 12.2% 
(8.9%-16.1%), respectively. Lung cancer patients were classified into 2 groups, 
high and low, on the basis of the median value of AIMP2-DX2, AIMP2, and 
AIMP2-DX2/AIMP2 ratio.
7. Statistics.
Significant differences in clinical characteristics according to AIMP2-DX2 
expression determined by IHC in lung tissues, and AIMP2-DX2, AIMP2, and 
AIMP2-DX2/AIMP2 autoantibodies ratio were analyzed using the χ2-test, 
Fisher’s exact test, and independent 2-sample t-test. Predictive factors for 
overall survival (OS) and progression/recurrence-free survival (PFS) were 
calculated using the Kaplan-Meier method and Cox proportional hazards 
model. Diagnostic usefulness was evaluated by receiver operative characteristic 
(ROC) curve generation. All tests for significance were 2-tailed, and P-values less 
10
than 0.05 were interpreted as statistically significant. All analyses were performed 
using the SPSS version 23 (SPSS Inc., Chicago, IL, USA).
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III. RESULTS
1. AIMP2-DX2 in lung cancer
가. AIMP2-DX2 is frequently and specifically overexpressed in lung cancer 
compared to non-neoplastic lung tissue in mouse and human.
To explore AIMP2-DX2 as a biomarker of lung cancer, its expression was 
evaluated in non-neoplastic lung tissue from 8-week-old wild type C57BL/6 mice 
(Fig. 1A). The majority of the cells in alveolar structure did not express AIMP2-
DX2 while bronchial epithelial cells showed weak expression.
Figure 1A. Weak AIMP2-DX2 expression in non-neoplastic mouse lung tissue as 
determined by immunohistochemistry.
AIMP2-DX2 expression was also evaluated in normal tissues adjacent to lung 
cancer (Fig. 1B). AIMP2-DX2 was not expressed in type I or type II pneumocytes 
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that comprise alveolar structures, and it was weakly expressed in the epithelial cells
of bronchioles and bronchi.
Figure 1B. Weak AIMP2-DX2 expression in normal adjacent human lung tissue as 
determined by immunohistochemistry.
To evaluate if AIMP2-DX2 expression was specific to lung cancer, its expression 
was evaluated in lung cancer tissues. Lung cancer-specific AIMP2-DX2 
overexpression was observed in LSL K-ras G12D and LSL K-ras G12D:p53fl/fl 
murine lung cancer models induced by AdCre inhalation (Fig. 1C). Lung cancer 
specific AIMP2-DX2 overexpression was further evaluated by immunoblotting of 
lung tissue lysates from wild type mouse and lung cancer model mouse (Fig. 1D). 
Stronger AIMP2-DX2 expression was observed in mouse lung cancer tissues than in 
wild type normal lung tissue.
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Figure 1C. AIMP2-DX2 expression in LSL K-ras G12D:p53fl/fl murine lung cancer 
tissue.
Figure 1D. AIMP2-DX2 expression in mouse lung cancer tissues and wild type 
normal lung tissues by immunoblotting.
Lung cancer-specific AIMP2-DX2 overexpression was further evaluated by 
immunoblotting of lysates from human lung cancer tissues and adjacent normal 
lung tissues. The baseline characteristics of 12 patients are shown in Table 1.
Among the 12 pairs of cancer and normal tissue lysates, 7 pairs showed 
overexpression of AIMP2-DX2 in lung cancer tissue compared to adjacent normal 
lung tissue (Fig. 1E).
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Table 1. Baseline characteristics of 12 lung cancer patients
No. Gender Age cell type Differentiation smoking
pack-
year
TNM Stage
EGFR 
mutation
KRAS
mutation
CEA 
(ng/mL)
1 F 76 Adeno - never 0 T3N0M0 IIB 0 0 51.72
2 F 48 Adeno acinar type never 0 T1aN2M0 IIIA 1 0 2.19
3 M 75 Adeno
solid 
predominant
former 30 T2aN0M0 IB 0 0 5.49
4 F 75 Adeno
papillary 
predominant
never 0 T1bN0M0 IA 0 0 1.95
5 M 67 Squamous - never 0 T2aN0M0 IB - - 3.41
6 M 68 Squamous moderate current 55 T2aN1M0 IIA - - 9.24
7 M 65 Squamous poor former 40 T2aN0M0 IB - - 4.09
8 M 62 Adeno
micropapillary 
predominant 
pattern
former 48 T2aN1M0 IIA 1 0 -
9 M 59 Adeno
micropapillary 
predominant 
with 
extracellular 
mucin 
formation
current 39 T2aN2M0 IIIA 1 0 4.33
10 M 71 Adeno
acinar 
predominant
current 92 T1bN2M0 IIIA 0 0 3.18
11 M 66 Squamous moderate former 25 T2bN2M0 IIIA - - 2.38
12 F 74 Adeno
acinar 
predominant
never 0 T2aN0M0 IB 1 0 3.08
Figure 1E. AIMP2-DX2 overexpression was observed in lung cancer tissue of 
patients 3, 6, 7, 8, 10, 11, and 12, and was related with mTORC1 activity (p-
p70S6K, p-S6, and total S6)(N: normal, T: tumor).
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To determine whether other proteins were associated with AIMP2-DX2 
overexpression, signaling molecules related to the mammalian target of rapamycin 
(mTOR) pathway were evaluated by immunoblotting human lung cancer and 
adjacent normal lung tissue lysates from the patients described in Table 1. mTOR 
serves as a central regulator of cell metabolism, growth, proliferation and survival, 
which is also a pivotal role of AIMP2.6,12 AIMP2-DX2 level was related to 
mTORC1 activity (p-p70S6K, p-S6, and total S6) more than it was related to 
mTORC2 activity (Fig. 1E).  Taken together, AIMP2-DX2 expression was 
frequently detected and highly specific to lung cancer, suggesting it can be a 
candidate for lung cancer diagnosis or therapy.
나. Overexpression of AIMP2-DX2 in lung cancer is related with Bcl-xL.
To investigate the relationship of AIMP2-DX2 with different types of aminoacyl-
tRNA synthetases and anti-apoptotic molecules, the correlation of AIMP2-DX2
expression with MRS, LRS, p-S6, Bcl-xL, KRAS, and HSP70 was determined by 
immunohistochemistry (Fig. 2A). A significant positive correlation was observed 
between AIMP2-DX2 and Bcl-xL (r=0.196, P = 0.011)(Table 2). 
16
Figure 2A. Expression of MRS, LRS, p-S6, Bcl-xL, KRAS, and HSP70 in human 
lung cancer tissue as determined by immunohistochemistry.
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Table 2. Correlation between AIMP2-DX2 expression and expression of related 
molecules
Related molecules No. of cases Pearson correlation coefficient P-value
MRS 172 0.028 0.661
LRS 117 0.053 0.503
p-S6 (Ser235/236) 114 -0.016 0.839
Bcl-xL 114 0.196 0.011
KRAS 120 0.033 0.673
HSP70 118 -0.143 0.065
다. DN-STAT3 inhibits AIMP2-DX2 expression by down-regulating SRSF1.
A previous report conducted serine/arginine-rich (SR) protein-binding motif 
analysis in exon 2 with the exonic splicing enhancer (ESE) finder program ver. 3.0 
to identify splicing factors involved in the deletion of AIMP2 exon 2.3 Analysis 
found that ESEs for serine/arginine-rich splicing factor 1 (SRSF1) were located in
mutated sites of exon 2.3 SRSF1 is a member of the SR protein family, which is 
involved in constitutive and alternative splicing.13 SRSF1 expression is up-regulated 
in several human neoplasms, including lung cancer, and participates in the 
establishment and maintenance of a transformed phenotype.14 SRSF1 expression 
was evaluated in relation to AIMP2-DX2 by immunoblotting of human lung cancer
and adjacent normal lung tissue lysates from the 12 lung cancer patients described 
in Table 1. Among the 7 patients exhibiting SRSF1 overexpression, 5 patients also
showed AIMP2-DX2 overexpression (Fig. 3A).
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Figure 3A. Among 7 patients with SRSF1 overexpression, 5 patients (patient 3, 6, 7, 
8, and 10) also showed AIMP2-DX2 overexpression as determined by 
immunoblotting.
To further explore the relationship between SRSF1 and AIMP2-DX2, the same 
immunoblotting strategy was applied to 9 lung cancer cell lines. However, these in 
vitro experiments showed that SRSF1 expression was not closely related with 
AIMP2-DX2 expression, because only 4 lung cancer cell lines (A549, H460, H1299, 
and H2009) showed simultaneous overexpression of SRSF1 and AIMP2-DX2 (Fig.
3B).
Figure 3B. Expression of SRSF1 and AIMP2-DX2 in various lung cancer cell lines 
as determined by immunoblotting.
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To evaluate the functional significance of SRSF1 on AIMP2-DX2 expression, 
SRSF1 was overexpressed in A540 and H460 cells or was down-regulated with a 
specific siRNA. Forced expression of SRSF1 using an SRSF1 expression vector did 
not increase AIMP2-DX2 expression (Fig. 3C). However, SRSF1 knockdown 
partially decreased AIMP2-DX2 level (Fig. 3D).
Figure 3C. SRSF1 overexpression in A549 and H460 lung cancer cell lines did not 
increase AIMP2-DX2 expression.
Figure 3D. SRSF1 knockdown partially down-regulated AIMP2-DX2 expression in 
A549 and H460 lung cancer cell lines.
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Since partial down-regulation of AIMP2-DX2 expression was observed upon 
SRSF1 knockdown, we evaluated whether signal transducer and activator of 
transcription 3 (STAT3) was an upstream regulator of AIMP2-DX2. According to 
our analysis of the relationship between AIMP2-DX2 and anti-apoptotic molecules 
by IHC (Table 2), Bcl-xL expression was significantly correlated with AIMP2-DX2. 
STAT3, a transcription factor, promotes Bcl-xL expression, which is associated 
with cell survival and proliferation.15,16 To further explore the relationship between
AIMP2-DX2, SRSF1, and Bcl-xL, STAT3 was inhibited in cells by expressing a 
dominant negative construct. STAT3 knockdown decreased SRSF1, AIMP2-DX2, 
and Bcl-xL expression (Fig. 3E). Therefore, STAT3 and SRSF1 are possible
regulators of AIMP2-DX2.
Figure 3E. STAT3 inhibition using a dominant negative construct decreased the 
expression of SRSF1, AIMP2-DX2, and Bcl-xL.
21
라. AIMP2-DX2 expression by immunohistochemistry is not prognostically useful 
for lung cancer. 
To further determine the clinical implications of AIMP2-DX2 in lung cancer, its 
expression was assessed by IHC in 275 paraffin-embedded human non-small cell 
lung cancer (NSCLC) tissues. The baseline characteristics of these 275 patients are 
shown in Table 3.
Table 3. Baseline characteristics of 275 cancer patientsa
Characteristics n= 275
Age, yr 61.3 ± 10.3
Male 206 (74.9)
Smoking status (n=256)
  Current 113 (44.1)
  Former 69 (27.0)
  Never 74 (28.9)
Stage
I 82 (29.8)
II 98 (35.6)
III 91 (33.1)
IV 4 (1.5)
Lung cancer cell type
  Adenocarcinoma 134 (48.7)
  Squamous cell carcinoma 134 (48.7)
  Other 7 (2.5)
a Data are presented as numbers (percentages) for categorical variables. Continuous variables are 
presented as means ± standard deviations.
AIMP2-DX2 was mainly expressed in the cytoplasm in lung cancer tissues. 
AIMP2-DX2 expression was graded with regards to intensity and frequency (Fig.
4A). The expression score was obtained by the product of intensity and frequency
scores. Distribution of cytoplasmic and nuclear expression scores of AIMP2-DX2 
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are shown in Table 4. Among the 275 patients, 270 (98.2%) lung cancer patients 
showed positive AIMP2-DX2 cytoplasmic expression while 91 (33.1%) patients 
showed positive nuclear expression.
Figure 4A. Representative immunohistochemical images of cytoplasmic and nuclear 
AIMP2-DX2 expression in lung cancer.
Table 4. Distribution of AIMP2-DX2 expression in cytoplasm and nucleus by 
immunohistochemistry
AIMP2-DX2 Expression Cytoplasm, n (%) Nucleus, n (%)
0 5 (1.8) 184 (66.9)
1 0 (0) 23 (8.5)
2 17 (6.2) 25 (9.1)
3 104 (37.8) 29 (10.5)
4 15 (5.5) 7 (2.5)
6 92 (33.5) 5 (1.8)
9 42 (15.2) 2 (0.7)
To determine the clinical implications of AIMP2-DX2 expression in lung cancer, 
the patients were classified into 2 groups, high and low expression, according to the 
AIMP2-DX2 expression in the cytoplasm and nucleus. Clinical and pathologic 
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characteristics are compared between the groups in Table 5. Age, sex, smoking 
status, and tumor size were not different between the groups. However, high 
cytoplasmic expression (39.6% vs. 28.6%, P = 0.055) tended to be more frequently 
observed and high nuclear expression (42.9% vs. 30.4%, P = 0.042) was 
significantly more frequent in advanced stages (III-IV) than in earlier stages (I-II).
Table 5. Baseline characteristics of high and low AIMP2-DX2 expression groups in
the cytoplasm and nucleusa
Cytoplasmic expression Nuclear expression
Characteristics
Low
(0-3)
High
(4-9) P-
value
Low
(0)
High
(≥1) P-
value
n=126 n=149 n=184 n=91
Age, yr 61.9 ± 9.8 61.4 ± 10.0 0.687 61.7 ± 9.7 61.6 ± 10.3 0.970
Male 94 (74.6) 112 (75.2) 0.914 138 (75.0) 68 (74.7) 0.961 
Ever smokers 88 (75.2) 94 (67.6) 0.213 124 (72.5) 58 (68.2) 0.477 
Size > 3cm 88 (47.6) 97 (52.4) 0.351 124 (67.0) 61 (33.0) 0.904 
Stage
I-II 90 (71.4) 90 (60.4)
0.055 
128 (69.6) 52 (57.1)
0.042 
III-IV 36 (28.6) 59 (39.6) 56 (30.4) 39 (42.9)
Pathology (n=268)
Adenocarcinoma 49 (40.2) 85 (58.2)
0.003
82 (45.8) 52 (58.4)
0.052
Squamous cell ca 73 (59.8) 61 (41.8) 97 (54.2) 37 (41.6)
a Data are presented as numbers (percentages) for categorical variables. Continuous variables are 
presented as means ± standard deviations.
AIMP2-DX2 expression level was not related with clinical outcome, showing no 
significant differences in OS or PFS by Kaplan-Meier curves (Fig. 4B).
24
Figure 4B. Kaplan-Meier curves for overall survival and progression/recurrence 
free-survival in high and low AIMP2-DX2 expression groups in the cytoplasm and 
nucleus. Expression of AIMP2-DX2 was not related with clinical outcome. P-value 
was obtained by log-rank test.
2. Autoantibodies against AIMP2-DX2 and AIMP2
가. Autoantibodies against AIMP2-DX2 and AIMP2 are detected in serum of 
lung cancer patients.
To further evaluate the diagnostic validity of AIMP2-DX2, the level of 
autoantibodies against AIMP2-DX2 and AIMP2 were measured in the serum of 
controls and lung cancer patients. The baseline characteristics of age, gender, and 
smoking status were not different between control (n=80) and lung cancer (n=80)
groups (Table 6). The distribution of autoantibody levels against AIMP2-DX2 and 
AIMP2, and AIMP2-DX2/AIMP2 ratio are shown with histograms (Fig. 5A).
25
Table 6. Baseline characteristics of controls and lung cancer patients a
a Data are presented as numbers (percentages) for categorical variables. Continuous variables are 
presented as means ± standard deviations.
Figure 5A. Histograms for the autoantibodies against AIMP2-DX2 and AIMP2, and 
AIMP2-DX2/AIMP2 ratio in controls and lung cancer patients.
According to the ROC curves, the AUCs of autoantibodies against AIMP2-DX2 and 
AIMP2, and AIMP2-DX2/AIMP2 ratio were 0.416, 0.579, and 0.354, respectively, 
suggesting that these parameters have limited diagnostic value in lung cancer (Fig.
5B).
Baseline characteristics
Control
(n=80)
Lung cancer
(n=80)
P-value
Age 68.2 ± 12.5 68.5 ± 9.3 0.869
Gender, male 63 (78.8) 61 (76.3) 0.705
Smoking status, ever-smoker 59 (73.8) 59 (73.8) 1.000
Pack years (including never smokers) 32.6 ± 28.8 35.5 ± 30.5 0.549
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Figure 5B. ROC curve analysis indicating the diagnostic value of autoantibodies 
against AIMP2-DX2 and AIMP2, and AIMP2-DX2/AIMP2 ratio in lung cancer.
나. Higher level of autoantibody against AIMP2-DX2 in patients with lung 
adenocarcinoma
Levels of autoantibodies against AIMP2-DX2 and AIMP2, and AIMP2-
DX2/AIMP2 ratio were measured and analyzed in 165 lung cancer patients. Their 
baseline characteristics are demonstrated in Table 7. The mean age was 65 years old 
and 64.8% were male. About one third of patients were never smokers. According 
to histologic classification, adenocarcinoma was the most common type (62.4%) 
and squamous cell carcinoma was second most common (25.5%). The levels of 
autoantibodies toward AIMP2-DX2 and AIMP2, and AIMP2-DX2/AIMP2 ratio 
were 21.6 AU, 76.7 AU, and 31.7, respectively. The distributions of these levels are 
shown using histograms (Fig. 6).
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Table 7. Baseline characteristics of 165 lung cancer patientsa
Characteristics n=165 (%)
Age, yr 65.3 ± 9.4
Sex, male 107 (64.8)
Smoking status
Current 58 (35.2)
Former 50 (30.3)
Never 57 (34.5)
Histology
Adenocarcinoma 103 (62.4)
Squamous cell carcinoma 42 (25.5)
Small cell carcinoma 16 (9.7)
Large cell carcinoma 4 (2.4)
Size > 3cmb 23 (18.5)
Stage (n=149)c
I 47 (31.5)
II 8 (5.4)
III 36 (24.2)
IV 58 (38.9)
Tumor markers
Elevated CEAd 74 (49.3)
Elevated CYFRA 21-1e 68 (47.6)
Parameters
AIMP2-DX2, AU 21.6 ± 9.2
AIMP2, AU 76.7 ± 33.8
AIMP2-DX2/AIMP2 31.7 ± 13.8
Mortality (n=163)f 82 (50.3)
a Data are presented as numbers (percentages) for categorical variables. Continuous variables are 
presented as means ± standard deviations.
b n=124
c Small cell carcinoma was excluded
d n=150, > 5.0 ng/mL
e n=143, > 3.3 ng/mL
f Survival of two patients are unknown
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Figure 6. Histograms for levels of autoantibodies against AIMP2-DX2 and AIMP2, 
and AIMP2-DX2/AIMP2 ratio in lung cancer patients.
To explore the clinical relevance of autoantibodies against AIMP2-DX2, AIMP2, 
and AIMP2-DX2/AIMP2 ratio in lung cancer, patients were classified into two 
groups, high and low, based on the median value of AIMP2-DX2 and AIMP2, and 
AIMP2-DX2/AIMP2 ratio (Table 8). There was no statistical difference between 
the gender, smoking status, histologic diagnosis, or tumor stages between high and 
low groups of autoantibodies toward AIMP2-DX2 and AIMP2, and AIMP2-
DX2/AIMP2 ratio. However, age (66.8 yr vs. 63.8 yr, P = 0.040) and proportion of 
tumor size larger than 3 cm (26.9% vs. 12.7%, P = 0.045) was higher in the high 
AIMP2-DX2 ratio group compared to the low group. An elevated CYFRA-21 level
was more frequently observed in the high AIMP2-DX2/AIMP2 ratio group than in 
the low ratio group (58.8% vs. 41.2%, P = 0.037) while the proportion of patients 
with elevated CEA level was similar between the groups. Moreover, the mortality 
rate was higher in the high AIMP2-DX2/AIMP2 ratio group than in the low ratio 
group (58.5% vs. 42.0%, P = 0.034).
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Table 8. Comparison between high and low AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 autoantibodies ratioa
Characteristics
AIMP2-DX2 AIMP2 AIMP2-DX2/AIMP2 ratio
Low High
P-value
Low High
P-value
Low High
P-value
(n=82) (n=83) (n=82) (n=83) (n=82) (n=83)
Age, yr 63.8 ± 10.1 66.8 ± 8.4 0.040 64.1 ± 9.4 66.5 ± 9.3 0.113 64.7 ± 9.5 65.9 ± 9.2 0.443
Sex, male 52 (63.4) 55 (67.1) 0.623 51 (62.2) 56 (67.5) 0.478 54 (65.9) 53 (63.9) 0.788
Smoking
Current 32 (39.0) 26 (31.7) 27 (32.9) 31 (37.3) 29 (35.4) 29 (34.9)
Former 23 (28.0) 27 (32.9) 0.603 23 (28.0) 27 (32.5) 0.484 27 (32.9) 23 (27.7) 0.686
Never 27 (32.9) 29 (35.4) 32 (39.0) 25 (30.1) 26 (31.7) 31 (37.3)
Histology
Adenocarcinoma 55 (67.1) 48 (57.3)
0.478
53 (64.6) 50 (60.2)
0.216
53 (64.6) 50 (60.2)
0.580
Squamous cell carcinoma 18 (22.0) 24 (29.2) 16 (19.5) 26 (31.3) 20 (24.4) 22 (26.5)
Small cell carcinoma 8 (9.7) 8 (9.8) 10 (12.2) 6 (7.2) 7 (8.5) 9 (10.8)
Large cell carcinoma 1 (1.2) 3 (3.7) 3 (3.7) 1 (1.2) 2 (2.4) 2 (2.4)
Size > 3cm 9 (12.7) 14 (26.9) 0.045 12 (18.2) 11 (19.0) 0.911 13 (20.0) 10 (16.9) 0.662
Stage (n=149)
I-II 34 (41.5) 27 (33.3) 0.284 28 (34.1) 34 (41.5) 0.334 36 (44.4) 45 (55.6) 0.083
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a Data are presented as numbers (percentages) for categorical variables. Continuous variables are presented as means ± standard deviations.
b n=75 for low group, n=75 for high group
c n=72 for low group, n=71 for high group
III-IV 48 (58.5) 54 (66.7) 54 (65.9) 48 (58.5) 26 (31.3) 57 (68.7)
Tumor markers
Elevated CEAb 42 (56.8) 32 (43.2) 0.119 40 (54.1) 34 (45.9) 0.193 35 (47.3) 39 (52.7) 0.514
Elevated CYFRA-21c 38 (55.9) 30 (44.1) 0.307 37 (54.4) 31 (45.6) 0.278 28 (41.2) 40 (58.8) 0.037
Mortality 37 (45.1) 45 (56.3) 0.157 42 (51.9) 40 (48.8) 0.695 34 (42.0) 48 (58.5) 0.034
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다. Elevated AIMP2-DX2/AIMP2 autoantibody ratio was related to poor lung 
cancer outcome.
To further evaluate the relationship of autoantibodies against AIMP2-DX2 and
AIMP2, and AIMP2-DX2/AIMP2 ratio with clinical outcomes, OS and PFS of the 
two groups were compared using Kaplan-Meier estimators (Fig. 7). There were no 
significant differences in OS and PFS between high and low AIMP2-DX2 and 
AIMP2 autoantibody groups. However, high AIMP2-DX2/AIMP2 ratio group 
showed significantly shorter OS compared to the low ratio group (18.4 months vs. 
48.3 months, P = 0.021)(Table 9).
Figure 7. Kaplan-Meier curves for overall survival and progression/recurrence free 
survival in high and low groups for autoantibodies against AIMP2-DX2 and AIMP2, 
and AIMP2-DX2/AIMP2 autoantibody ratio. High AIMP2-DX2/AIMP2 ratio was
significantly correlated with improved overall survival. P-value was obtained by 
log-rank test.
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Table 9. Median overall survival and progression/recurrence free survival in high 
and low AIMP2-DX2, AIMP2, and AIMP2-DX2/AIMP2 autoantibodies ratio
Median
AIMP2-DX2 AIMP2 AIMP2-DX2/AIMP2 ratio
Low High Low High Low High
OS months
(95% CI)
- 21.1
(13.04-29.37)
21.4
(-)
27.9
(15.64--40.17)
48.3
(14.62-81.98)
18.4
(15.09-21.70)
PFS months
(95% CI)
14.9
(10.12-19.68)
15.0
(6.20-23.79)
13.9
(8.67-19.13)
17.5
(8.14-26.86)
16.2
(9.71-22.69)
10.7
(6.61-14.79)
To evaluate the hypothesis that high AIMP2-DX2/AIMP2 autoantibodies ratio is an 
independent prognostic factor in lung cancer, univariate and multivariate analyses 
were performed using a Cox regression hazard model (Table 10). Univariate 
analysis revealed that age, female sex, ever-smoker, advanced stage (III-IV), 
elevated CEA level, elevated CYFRA-21 level, and high AIMP2-DX2/AIMP2 ratio 
were significant predictors of poor OS while adenocarcinoma histology was a 
significant predictor of better OS. Multivariate analysis showed that advanced 
stages (III-IV)(HR = 6.66, 95% CI 3.20-13.89) and high AIMP2-DX2/AIMP2 
ratio (HR = 1.83, 95% CI 1.11-3.01) were significant independent factors for poor 
OS while adenocarcinoma histology (HR = 0.42, 95% CI 0.23-0.76) was a 
predictor for better OS.
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Table 10. Univariate and multivariate Cox-regression analysis of overall survival
Characteristics
Univariate Analysis Multivariate Analysis
HR P-value 95% CI HR P-value 95% CI
Age, yr 1.03 0.022 1.01-1.06 1.02 0.201 0.99-1.05
Sex, female 0.53 0.011 0.32-0.86 0.76 0.655 0.22-2.58
Smoking, ever-smoker 1.71 0.029 1.06-2.77 1.12 0.858 0.33-3.77
Histology
Adenocarcinoma 0.54 0.006 0.35-0.84 0.42 0.004 0.23-0.76
Squamous cell carcinoma 1.51 0.084 0.95-2.42
Size > 3 cm 0.56 0.180 0.24-1.31
Stage, stage III-IV vs. I-II 6.71 < 0.001 3.45-13.05 6.66 < 0.001 3.20-13.89
Tumor markers
Elevated CEA 1.92 0.007 1.20-3.07 1.44 0.176 0.85-2.42
Elevated CYFRA-21 2.98 < 0.001 1.82-4.86 1.40 0.231 0.81-2.41
High level of
AIMP2-DX2 1.28 0.263 0.83-1.98
AIMP2 0.88 0.579 0.57-1.37
AIMP2-DX2/AIMP2 1.67 0.023 1.07-2.60 1.83 0.018 1.11-3.01
HR: hazard ratio, CI: confidence interval
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IV. DISCUSSION
This study demonstrated a mechanism related with AIMP2-DX2 expression and 
elucidated the clinical implication of AIMP2-DX2 overexpression in lung cancer. 
AIMP2-DX2 was specifically overexpressed in human and mouse lung cancer 
tissues compared to adjacent normal tissues. Expression of AIMP2-DX2 in lung 
cancer was related with mTORC1 signaling activity and was positively correlated 
with expression of the anti-apoptotic protein, Bcl-xL. Down-regulation of SRSF1 
partially decreased AIMP2-DX2 expression. STAT3 inhibition decreased expression 
of SRSF1, AIMP2-DX2, and Bcl-xL. IHC analysis showed that AIMP2-DX2 
expression in lung cancer tissue was associated with advanced stage and histology 
subtypes although its validity in relation to clinical outcome was limited. 
Autoantibodies against AIMP2-DX2 and AIMP2 existed at detectable levels in 
human blood. Increased level of the ratio between autoantibodies for AIMP2-DX2
and AIMP2 was an independent prognostic factor for poor OS in patients with lung 
cancer.
AIMP2 plays an important role in controlling cell fate. It demonstrates anti-
proliferative activity by enhancing growth-arresting TGF-b signaling.4 AIMP2 also 
promotes cell death through activating p53 and the apoptotic signaling of TNF-a.5,6
AIMP2-DX2 competes with AIMP2 for binding to FBP, TRAF2, and p53, 
consequently interrupting the tumor-suppressive roles of AIMP2.3,10
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To explore the molecules related with the AIMP2-DX2 overexpression, signaling 
molecules involved in the mTOR pathway were evaluated. AIMP2-DX2 expression 
was related to the level of mTORC1, p-p70S6K, and p-S6. Elevated p70S6K has 
been found in many tumor cells and is related with increased tumor size, whereas 
inhibition of p70S6K prevents cell proliferation.17 shDX2 suppressed mTOR 
phosphorylation at p70S6K, regulating cancer growth and proliferation.8
STAT3 is a transcription factor activated by Janus kinase 1 (JAK1) and JAK2. After 
translocation from the cytoplasm to the nucleus, nuclear STAT3 transactivates 
numerous genes that sustain cellular survival and proliferation by promoting the 
expression of anti-apoptotic molecules including Bcl-xL.15,16 Down-regulation of 
STAT3 decreased SRSF1, AIMP2-DX2, and Bcl-xL expression. AIMP2-DX2 
expression may be induced by STAT3 directly or by SRSF1 through STAT3, 
because SRSF1 knockdown partially decreased AIMP2-DX2 expression.
Cytoplasmic-nuclear shuttling of AIMP2-DX2 is expected to scarcely occur because 
the AIMP2-DX2 sequence does not contain a nuclear localization sequence. In 
human lung cancer tissues, AIMP2-DX2 was expressed strongly in the cytoplasm of
98% of the patients but weakly expressed in the nucleus of a few patients.
Although autoantibodies against AIMP2-DX2 were detectable in the serum, 
whether AIMP2-DX2 or AIMP2 possesses stronger properties as a secretary protein 
has not been defined yet. Investigating the structure of AIMP2-DX2 and AIMP2 
would be helpful to explore the structural differences between AIMP2-DX2 and 
AIMP2. Then, hydrophilicity and hydrophobicity of those could be predicted.
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Previous studies demonstrated the essential role of AIMP2-DX2 in tumorigenesis, 
but only few studies have evaluated the possible role of AIMP2-DX2 as a biomarker 
for diagnosis, treatment, and prognosis in lung cancer. Besides lung cancer, AIMP2-
DX2 was investigated whether it can be an effective target for overcoming 
chemoresistance in ovarian cancer.10 It was found that the direct delivery of siRNA 
against AIMP2-DX2 into abdominal ovarian cancer metastases significantly 
suppressed the growth rate of tumors in a mouse model of ovarian cancer 
suggesting that AIMP2-DX2 down-regulation can be a potent adjuvant therapeutic 
approach for chemoresistant epithelial ovarian cancer through aberrant NF-kB 
activity.10
High AIMP2-DX2 expression in tissues as determined by IHC was related with 
advanced disease stage and was more frequent in adenocarcinoma than squamous 
cell carcinoma. Unlike the previous study, this study could not demonstrate the 
prognostic value of AIMP2-DX2 to predict mortality and disease progression. This 
discrepancy may be related with different methods of detecting AIMP2-DX2 and 
AIMP2, and a different definition of high expression.3
This study showed that the ratio of autoantibodies against AIMP2-DX2/AIMP2 is a 
potential prognostic biomarker for lung cancer. The prognostic validity of 
autoantibody level was investigated in lung cancer patients with evenly distributed 
cancer stages. Most current lung cancer biomarkers identify gene mutations. KRAS, 
Epidermal Growth Factor Receptor (EGFR), and anaplastic lymphoma kinase (ALK) 
are common biomarkers seen in NSCLC.18 The KRAS gene is mutated in about 25% 
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of NSCLC patients and EGFR is defective in about 10% of NSCLC patients (nearly 
50% of lung cancer patients never smoked) while ALK gene rearrangements occur 
in up to 5 % of NSCLC patients.18 The relationship between AIMP2-DX2 and 
KRAS was evaluated, but AIMP2-DX2 was not correlated with KRAS. Moreover, 
the group with low AIMP2-DX2 and KRAS expression and the group with high 
AIMP2-DX2 and KRAS expression showed similar OS and PFS (data not shown). 
However, these comparisons were only determined by IHC, so further investigation 
is required with more quantitative and qualitative measurement of biomarkers. For 
this purpose, methods of directly measuring AIMP2-DX2 and AIMP2 in the blood 
need to be developed.
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V. CONCLUSION
In conclusion, AIMP2-DX2 expression was specifically overexpressed in lung 
cancer tissues. Expression of AIMP2-DX2 was related with mTORC1 activity and 
was correlated with Bcl-xL expression. SRSF1 knockdown partially decreased 
AIMP2-DX2 level, and STAT3 inhibition down-regulated the expression of SRSF1, 
AIMP2-DX2 and Bcl-xL. This suggests that STAT3 and SRSF1 regulate AIMP2-
DX2 expression. Autoantibodies against AIMP2-DX2 and AIMP2 were detectable 
in the serum and the ratio of autoantibodies against AIMP2-DX2/AIMP2 was an 
independent significant prognostic factor for poor clinical outcome in lung cancer 
patients. Although this study suggests that AIMP2-DX2 is a new possible 
prognostic biomarker in lung cancer, further studies are necessary to explore 
AIMP2-DX2 as a biomarker for diagnosis, therapeutic guidance, and prediction of 
disease recurrence/progression.
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ABSTRACT (IN KOREAN)
폐암에서 aminoacyl-tRNA synthetase complex interacting multi-
functional protein 2–exon 2 deletion 이형의 임상적 의의
<지도교수 장준>
연세대학교 대학원 의학과
정 지 예
배경: Aminoacyl-tRNA synthetase interacting multi-functional 
protein 2 (AIMP2) 는 p53과 TNF-α 신호 전달 경로를 통해 세포사를 유
도한다. AIMP2의 RNA 대체 접합 (alternative splicing)으로 exon 2가
결실이 된 AIMP2-exon 2 deletion (AIMP2-DX2)은 표적 단백에 AIMP2와
경쟁적으로 결합하여, AIMP2의 종양 억제 기능을 방해한다. 본 연구에는
폐암에서의 AIMP2-DX2 과발현의 임상적 의미와 기전을 탐구하고자 하였
다.
방법: AIMP2-DX2 발현을 폐암 쥐 모델과 수술적 치료 후 얻어진 폐암 환
자의 조직에서 면역조직화학법과 면역학적 블로팅으로 분석하였다. 폐암
환자와 대조군의 혈청에서 효소결합 면역흡수 분석법을 이용하여, 
AIMP2-DX2와 AIMP2에 대한 자가 항체 농도를 측정하였다. 분석 및 측정
된 결과는 임상적 요소들과 비교 분석하여, 의의를 조사하였다.
결과: 폐암 생쥐 모델과 폐암 환자의 폐암과 정상 조직을 이용한 실험에
서 AIMP2-DX2는 폐암조직에서의 특이적 과발현이 58%에서 관찰되었다. 
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폐암 조직에서 AIMP2-DX2의 과발현은 mTORC1 신호 전달 경로의 활성과
뚜렷한 관련이 없었고, 다양한 aminoacyl-tRNA synthetase와 항고사 단
백 발현과의 상관관계분석 결과 Bcl-xL 발현과 양의 상관관계를 보였다. 
폐암 세포주인 A549와 H460에 signal transducer and activator of 
transcription 3 (STAT3)의 우성음성돌연변이체 플라스미드 형질주입으
로 억제하였을 때, serine/arginine-rich splicing factor 1 (SRSF1), 
AIMP2-DX2, 그리고 Bcl-xL 발현이 감소하였다. SRSF1 억제는 AIMP2-DX2
발현을 일부 감소시켜, AIMP2-DX2는 STAT3에 의해 발현되며, 일부는
SRSF1에 의해 발현되는 것임을 확인하였다. 폐암 환자와 대조군 혈액에
서 AIMP2-DX2와 AIMP2 자가 항체 측정을 통해 검출이 가능함을 확인하였
다. 폐암 환자의 혈액에서 AIMP2-DX2/AIMP2 비율이 높은 군은 낮은 군에
비해서 생존율이 낮으며 (18.4 개월 vs. 48.3개월; P = 0.021), AIMP2-
DX2/AIMP2의 높은 비율은 폐암환자의 독립적인 예후 인자로 의의가 있었
다 (위험비 = 1.83, 95% 신뢰구간 1.11 - 3.01).
결론: 본 연구결과는 AIMP2-DX2 면역조직화학적 과발현이 폐암 진단에
유용하고, AIMP2-DX2/AIMP2의 자가 항체 비율 증가가 폐암 예후 예측에
유효한 바이오마커임을 시사한다. 따라서, AIMP2-DX2는 폐암의 표적 물
질로서의 개발에 지속적인 연구가 필요할 것으로 사료된다.
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